Activation of the NRF2 pathway, improvement in cell viability, reduction in superoxide concentration, and protection against rotenone were also demonstrated in tauopathy cell model HEK293 aggregate-positive cells treated with hydralazine (Supplementary Fig. 6a–e). The gene discussed is NFE2L2; the disease is tauopathy.